A new clinical trial highlighted in The Lancet journal has shown promising results for a yearly injection aimed at preventing HIV. The medication, known as ‘Lenacapavir’, developed by Gilead Sciences, has demonstrated safety and potential efficacy in protecting at-risk individuals.
About the Author
